title: The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure.
authors.affiliation: Leukemia Program and Department of Translational Hematology and Oncology Research, Cleveland Clinic, OH, USA.
authors.forename: Aziz
authors.initials: A
authors.lastname: Nazha
authors.affiliation: Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
authors.forename: Rami S
authors.initials: RS
authors.lastname: Komrokji
authors.affiliation: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Guillermo
authors.initials: G
authors.lastname: Garcia-Manero
authors.affiliation: Department of Quantitative Health Sciences, Cleveland Clinic, OH, USA.
authors.forename: John
authors.initials: J
authors.lastname: Barnard
authors.affiliation: Division of Hematology and Oncology, New York Presbyterian Hospital-Weill Cornell Medical College, NY, USA.
authors.forename: Gail J
authors.initials: GJ
authors.lastname: Roboz
authors.affiliation: Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
authors.forename: David P
authors.initials: DP
authors.lastname: Steensma
authors.affiliation: Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
authors.forename: Amy E
authors.initials: AE
authors.lastname: DeZern
authors.affiliation: Department of Quantitative Health Sciences, Cleveland Clinic, OH, USA.
authors.forename: Katrina
authors.initials: K
authors.lastname: Zell
authors.affiliation: Leukemia Program and Department of Translational Hematology and Oncology Research, Cleveland Clinic, OH, USA.
authors.forename: Cassie
authors.initials: C
authors.lastname: Zimmerman
authors.affiliation: Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
authors.forename: Najla Al
authors.initials: NA
authors.lastname: Ali
authors.affiliation: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Elias
authors.initials: E
authors.lastname: Jabbour
authors.affiliation: Division of Hematology and Oncology, New York Presbyterian Hospital-Weill Cornell Medical College, NY, USA.
authors.forename: Molly D
authors.initials: MD
authors.lastname: Greenberg
authors.affiliation: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Hagop M
authors.initials: HM
authors.lastname: Kantarjian
authors.affiliation: Leukemia Program and Department of Translational Hematology and Oncology Research, Cleveland Clinic, OH, USA.
authors.forename: Jaroslaw P
authors.initials: JP
authors.lastname: Maciejewski
authors.affiliation: Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
authors.forename: Alan F
authors.initials: AF
authors.lastname: List
authors.affiliation: Leukemia Program and Department of Translational Hematology and Oncology Research, Cleveland Clinic, OH, USA sekerem@ccf.org.
authors.forename: Mikkael A
authors.initials: MA
authors.lastname: Sekeres
mesh_terms: D000328:Adult; D001374:Azacitidine / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D000077209:Decitabine; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008297:Male; D008954:Models, Biological; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000401:mortality*; D011237:Predictive Value of Tests; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D000077209:Decitabine; D001374:Azacitidine
keywords: MDS; hypomethylating agent; prognostic models